XML 51 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Jan. 03, 2025
Dec. 29, 2023
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Value of Initial Fixed $100
Investment Based On:
Net Income
(millions)
($)
Net Product
Revenues
(millions)
($)(5)
Year
Summary
Compensation
Table Total for
PEO
($)(1)
Compensation
Actually Paid to
PEO
($)(1)(2)
Average
Summary
Compensation
Table Total for
Non-PEO NEOs
($)(1)
Average
Compensation
Actually Paid to
Non-PEO NEOs
($)(1)(2)
Total
Stockholder
Return
($)(3)
Peer Group
Total
Stockholder
Return
($)(4)
2024
12,732,048
39,392,518
4,119,867
11,247,723
200
122
521.3
1,809.4
2023
16,423,307
31,702,754
5,505,198
7,804,316
141
121
207.8
1,628.9
2022
16,877,545
16,020,538
5,149,608
5,038,751
94
116
182.3
1,401.2
2021
7,530,431
15,297,662
3,510,384
5,612,040
107
129
231.1
1,077.3
2020
2,349,812
18,565,411
1,237,199
5,878,678
118
129
111.8
741.6
        
Company Selected Measure Name Net Product Revenues        
Named Executive Officers, Footnote Dr. Morrissey was our PEO for each year presented. The individuals comprising the non-PEO NEOs for each year presented are as
follows: (i) for 2024, Mr. Senner, Dr. Aftab, Dr. Peterson and Mr. Hessekiel; (ii) for 2023, Mr. Senner, Dr. Aftab, Dr. Peterson, Dr.
Goodman and Mr. Hessekiel; (iii) for 2022, Mr. Senner, Dr. Goodman, Mr. Haley and Mr. Hessekiel; (iv) for 2021, Mr. Senner, Mr.
Haley, Mr. Hessekiel, Dr. Peter Lamb and Dr. Gisela M. Schwab; and (v) for 2020, Dr. Schwab, Mr. Senner, Mr. Hessekiel and Mr.
Haley. 		       
Peer Group Issuers, Footnote Represents the cumulative peer group TSR, weighted according to the respective companies’ stock market capitalization at the
beginning of each period for which a return is indicated. The peer group used for this purpose is the Nasdaq Biotechnology Index,
which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our annual reports for
each of the years in the table.
        
PEO Total Compensation Amount $ 12,732,048 $ 16,423,307 $ 16,877,545 $ 7,530,431 $ 2,349,812
PEO Actually Paid Compensation Amount $ 39,392,518 31,702,754 16,020,538 15,297,662 18,565,411
Adjustment To PEO Compensation, Footnote Compensation actually paid, as calculated under the SEC’s rules, requires making certain adjustments to the “Total” column of the
Summary Compensation Table to reflect the exclusion and inclusion of certain amounts for the PEO and the Non-PEO NEOs; the
tables set forth below reflect those adjustments. Equity values in the tables below are calculated in accordance with FASB ASC Topic
718. Amounts in the “Exclusion of Stock Awards and Options Awards” column of the tables below are the totals from the “Stock
Awards” and “Option Awards” columns set forth in the Summary Compensation Table. The differences between the amounts in the
“Total” column of the Summary Compensation Table and the “compensation actually paid” are primarily attributable to the
appreciation in the price of our common stock and the annual vesting of RSU and earned PSU awards, as well as the value recognized
upon or following achievement of performance targets for the PSU awards during the year. In addition, with respect to PSU awards
granted to the applicable NEOs during fiscal 2020, the grant date fair values of such awards, as computed in accordance with ASC
718, excluding the estimate of estimated forfeitures, are based upon the then-probable outcome of the performance conditions,
which was $0 for each NEO.
Year
Summary Compensation Table
Total for PEO
($)
Exclusion of Stock Awards
and Options Awards for PEO
($)
Inclusion of Equity Values for
PEO
($)
Compensation Actually Paid to
PEO
($)
2024
12,732,048
(10,012,388)
36,672,858
39,392,518
Year
Average Summary
Compensation Table Total for
Non-PEO NEOs
($)
Average Exclusion of Stock
Awards and Options Awards for
Non-PEO NEOs
($)
Average Inclusion of Equity
Values for Non-PEO NEOs
($)
Average Compensation Actually
Paid to Non-PEO NEOs
($)
2024
4,119,867
(3,013,432)
10,141,288
11,247,723
        
Non-PEO NEO Average Total Compensation Amount $ 4,119,867 5,505,198 5,149,608 3,510,384 1,237,199
Non-PEO NEO Average Compensation Actually Paid Amount $ 11,247,723 7,804,316 5,038,751 5,612,040 5,878,678
Adjustment to Non-PEO NEO Compensation Footnote Compensation actually paid, as calculated under the SEC’s rules, requires making certain adjustments to the “Total” column of the
Summary Compensation Table to reflect the exclusion and inclusion of certain amounts for the PEO and the Non-PEO NEOs; the
tables set forth below reflect those adjustments. Equity values in the tables below are calculated in accordance with FASB ASC Topic
718. Amounts in the “Exclusion of Stock Awards and Options Awards” column of the tables below are the totals from the “Stock
Awards” and “Option Awards” columns set forth in the Summary Compensation Table. The differences between the amounts in the
“Total” column of the Summary Compensation Table and the “compensation actually paid” are primarily attributable to the
appreciation in the price of our common stock and the annual vesting of RSU and earned PSU awards, as well as the value recognized
upon or following achievement of performance targets for the PSU awards during the year. In addition, with respect to PSU awards
granted to the applicable NEOs during fiscal 2020, the grant date fair values of such awards, as computed in accordance with ASC
718, excluding the estimate of estimated forfeitures, are based upon the then-probable outcome of the performance conditions,
which was $0 for each NEO.
Year
Summary Compensation Table
Total for PEO
($)
Exclusion of Stock Awards
and Options Awards for PEO
($)
Inclusion of Equity Values for
PEO
($)
Compensation Actually Paid to
PEO
($)
2024
12,732,048
(10,012,388)
36,672,858
39,392,518
Year
Average Summary
Compensation Table Total for
Non-PEO NEOs
($)
Average Exclusion of Stock
Awards and Options Awards for
Non-PEO NEOs
($)
Average Inclusion of Equity
Values for Non-PEO NEOs
($)
Average Compensation Actually
Paid to Non-PEO NEOs
($)
2024
4,119,867
(3,013,432)
10,141,288
11,247,723
        
Equity Valuation Assumption Difference, Footnote The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following
tables:
Year
Year End Fair
Value of Equity
Awards Granted
During Year That
Remained
Outstanding and
Unvested as of
Last Day of Year for
PEO
($)
Year over Year
Change in Fair Value
of Outstanding and
Unvested Equity
Awards Granted
in Prior Years for
PEO
($)
Fair Value as of
Vesting Date of
Equity Awards
Granted and
Vested During Year
for PEO
($)
Year over Year
Change in Fair
Value of Equity
Awards Granted
in Prior Years that
Vested During Year
for PEO
($)
Fair Value at Last
Day of Prior Year
of Equity Awards
Forfeited During
Year for PEO
($)
Total – Inclusion
of Equity Values for
PEO
($)
2024
19,215,182
17,032,540
—
425,136
—
36,672,858
Year
Average Year End
Fair Value of Equity
Awards Granted
During Year That
Remained
Outstanding and
Unvested as of Last
Day of Year for Non-
PEO NEOs
($)
Average Year over
Year Change in Fair
Value of Outstanding
and Unvested Equity
Awards Granted in
Prior Years for Non-
PEO NEOs
($)
Average Fair Value
as of Vesting Date of
Equity Awards
Granted and Vested
During Year for Non-
PEO NEOs
($)
Average Year over
Year Change in Fair
Value of Equity
Awards Granted in
Prior Years that
Vested During Year
for Non-PEO NEOs
($)
Average Fair Value
at Last Day of Prior
Year of Equity
Awards Forfeited
During Year for Non-
PEO NEOs
($)
Total – Average
Inclusion of Equity
Values for Non-PEO
NEOs
($)
2024
5,783,207
4,123,244
—
234,837
—
10,141,288
        
Compensation Actually Paid vs. Total Shareholder Return Required Disclosure of the Relationship Between Compensation Actually Paid and Financial Performance Measures
As required by Item 402(v) of Regulation S-K, we are providing the following graphs to illustrate the relationship of the
“compensation actually paid” figures that are included in the pay versus performance tabular disclosure above, to (1) our
cumulative TSR and that of the Nasdaq Biotechnology index, (2) our net income, and (3) our Net Product Revenues, which is
our company-selected measure. In addition, the first graph below further illustrates the relationship between our TSR and
that of the Nasdaq Biotechnology Index. As noted above, “compensation actually paid” for purposes of the tabular
disclosure and the following graphs was calculated in accordance with SEC rules and does not fully represent the actual final
amount of compensation earned by or actually paid to our NEOs during the applicable years. The graph assumes that $100
was invested on January 3, 2020 in each of our common stock and the Nasdaq Biotechnology Total Return Index and
assumes reinvestment of any dividends.
6225
        
Compensation Actually Paid vs. Net Income
6227
        
Compensation Actually Paid vs. Company Selected Measure
6229
        
Tabular List, Table
Relative TSR
Net Product Revenues
        
Total Shareholder Return Amount $ 200 141 94 107 118
Peer Group Total Shareholder Return Amount 122 121 116 129 129
Net Income (Loss) $ 521,300,000 $ 207,800,000 $ 182,300,000 $ 231,100,000 $ 111,800,000
Company Selected Measure Amount 1,809,400,000 1,628,900,000 1,401,200,000 1,077,300,000 741,600,000
PEO Name Dr. Morrissey        
Additional 402(v) Disclosure Represents the company’s cumulative TSR. Cumulative TSR is calculated by dividing (i) the sum of (a) the cumulative amount of
dividends for the measurement period, assuming dividend reinvestment, and (b) the difference between our share price at the end
and the beginning of the measurement period, by (ii) our share price at the beginning of the measurement period. The beginning of
the measurement period for each year in the table is January 3, 2020. Cumulative TSR is calculated assuming an investment of $100
in our common stock on January 3, 2020.
SEC rules require us to designate a “Company-Selected Measure” that in our assessment represents the most important financial
performance measure used by us to link the compensation actually paid to our PEO and non-PEO NEOs, for the most recently
completed fiscal year, to our performance. We have selected Net Product Revenues as this measure. 		       
Measure:: 1          
Pay vs Performance Disclosure          
Name Relative TSR        
Measure:: 2          
Pay vs Performance Disclosure          
Name Net Product Revenues        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (10,012,388)        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 36,672,858        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 19,215,182        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 17,032,540        
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 425,136        
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,013,432        
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 10,141,288        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 5,783,207        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 4,123,244        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 234,837        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 0